Popular Articles

National Audit Office Report On Supporting Adults With Autism
The NAO today published a major report, "Supporting people with autism through adulthood". HOPE, the charity for adults with autism and learning disabilities, sees this important report as a blueprint for improving the lives of people with autism.

Keep NHS General Practice Public For The Benefit Of Patients, Says British Medical Association
On Wednesday the BMA called on the Scottish Parliament Health Committee to support Government plans to remove the ability for commercial companies to provide NHS general practice services to patients.
News of the day
Health Affairs Study Finds No Link Between Cost, Quality Of Care
Quality of care is not linked to the cost of care, according to a study published last week on the Web site of the journal Health Affairs, CQ HealthBeat reports. For the study, researchers from Dartmouth College and Harvard University analyzed the health care bills of chronically ill Medicare beneficiaries in their last two years of life who received end-of-life care from 2,172 unidentified hospitals. The patients had one of three common conditions: heart attack, pneumonia or congestive heart failure. The study -- sponsored by the National Institute on Aging -- looked at common quality indicators at a hospital-by-hospital level instead of regional level (Norman, CQ HealthBeat, 5/22). Researchers compared the data with some of the quality measures reported on the HHS Hospital Compare Web site (Goldstein, "Health Blog," Wall Street Journal, 5/21). The study found that among the one-fifth of hospitals that spent the least, the cost of end-of-life care was $16,059 on average. In comparison, the cost of end-of-life care at the top 20% of highest-spending hospitals was $34,742 on average. The study also found no link -- or even evidence against a link -- between spending and the quality indicators. The researchers noted that the results might be skewed because the quality indicators they used might penalize hospitals that treat sicker patients. In addition, the study used process-of-care measures instead of patient outcomes. According to CQ HealthBeat, the findings of the study could have an effect on the debate over health care reform legislation because lawmakers and President Obama both have said that a reform plan must be able to control costs and expand access to high-quality, affordable health care (CQ HealthBeat, 5/22).
Oncology

SRI International To Screen Drugs That Fight 2009 H1N1 Influenza A

SRI International, an independent, nonprofit research and development organization, announced today that it will screen a library of well-characterized drugs against the 2009 H1N1 influenza A virus, previously known as "swine flu." The work will be performed under a re contract from the Division of Microbiology and Infectious Diseases (DMID) in the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. There is currently only one class of antiviral drugs, the neuraminidase inhibitors, available to treat this H1N1 infection. Identifying drugs from other chemical and mechanistic classes could provide more effective alternatives to current therapies and make it easier to provide sufficient quantities of drugs to a broad population, should the need arise. The development of new treatments may be expedited by screening drugs that have already well-characterized safety and toxicity profiles. "SRI has expertise in screening new and approved drugs, including the development of novel uses for antibiotics and screening a library of licensed drugs to find compounds that show efficacy against biothreat agents. SRI appreciates the opportunity to apply its knowledge and skills to screening drugs against H1N1 flu and contributing to the overall understanding of the virus," said Amy Shurtleff, Ph.D., a senior virologist in SRI International"s Biosciences Division, who will lead this screening program. Although the number of new 2009 H1N1 influenza A virus cases appears to be slowing worldwide, viruses are unpredictable. In particular, it is not known how this new virus will behave when the seasonal flu season returns this fall and in subsequent years. Scientists are looking at the Southern Hemisphere now, where the flu season will begin soon, for any signs of changes in the H1N1 virus and how humans respond to the infection. SRI has a long and successful history of drug discovery and development, which includes both screening of licensed drugs and finding and studying new chemical and biological therapeutics and vaccines. The virus will be handled in compliance with all guidelines prescribed by the Centers for Disease Control and Prevention (CDC) for handling this strain of influenza. SRI researchers will culture cell lines and study H1N1 virus growth under well-controlled conditions. Next, they will begin testing the first round of drugs. Assuming that some drugs show worthwhile efficacy and potency, SRI will help develop a plan for preclinical and clinical evaluation and regulatory approval. SRI International *See our Map Of H1N1 Outbreaks *See our Mexico Swine Flu Blog


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):